Year: 2017

Date Title
Dec 12, 2017 Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies
Dec 07, 2017 Pluristem to Present Data on PLX-R18 in Treatment of Acute Radiation Syndrome at American Society of Hematology’s Annual Meeting
Nov 29, 2017 Peer-Reviewed Article Published on Pluristem’s PLX-PAD Cells’ Mechanism of Action to Restore Blood Flow in Ischemic Tissue
Nov 22, 2017 Pluristem Granted Key U.S. Patent for Skeletal Muscle Regeneration – a Meaningful Asset Ahead of Upcoming Phase III Femoral Neck Fracture Study
Nov 14, 2017 Pluristem Reports First Quarter Fiscal 2018 Corporate and Financial Highlights
Nov 06, 2017 Pluristem Enters into Agreement with Tel Aviv Sourasky Medical Center to Conduct Phase I/II Trial in Steroid-Refractory Chronic GvHD
Oct 30, 2017 Pluristem announces pricing of public offering of common stock on the Tel Aviv Stock exchange
Oct 29, 2017 Pluristem proposes to launch a public offering of common stock on the Tel Aviv stock exchange after concluding an Israeli institutional investor tender
Oct 26, 2017 Following Approval of Israel’s Ministry of Health, Pluristem Extends its Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery after Bone Marrow Transplant and Opens Clinical Centers in Israel
Oct 23, 2017 Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases
Oct 19, 2017 FDA Grants Pluristem Orphan Drug Designation for Its PLX-R18 Cell Therapy as Treatment for Acute Radiation Syndrome
Oct 16, 2017 New Published Data Highlights the Potential of Pluristem’s PLX Cells in Improving Cardiac Function in Diabetes
Oct 02, 2017 $7.9 Million Granted to nTRACK Collaborative Project Designed to Study Pluristem’s PLX-PAD Cells
Sep 26, 2017 Pluristem Receives Positive Feedback from FDA and EMA as Company Prepares for Phase III Trial of PLX-PAD to Support Recovery from Hip Fracture
Sep 18, 2017 U.S. FDA Grants Fast Track Designation to Pluristem’s PLX-PAD for the Treatment of Critical Limb Ischemia (CLI)
Sep 13, 2017 Pluristem Strengthens Its Position in Asia, Awarded Two New Patents in Hong Kong for Critical Limb Ischemia and Muscle Regeneration
Sep 11, 2017 Pluristem Reports Fourth Quarter and Fiscal 2017 Corporate and Financial Highlights
Sep 05, 2017 $8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program
Aug 16, 2017 U.S. Department of Defense to Conduct Studies of Pluristem’s PLX-R18 in a New ARS Project for Use Before Radiation Exposure
Aug 09, 2017 Israeli Government to Support Pluristem’s Marketing Activity in China; Ministry of Economy Awards Company “Smart Money” Grant
Jul 26, 2017 New Data from ARS Study Shows Significant Hematological Deficiencies Even at Low Radiation Levels; PLX-R18 Supports Hematological Recovery
Jul 10, 2017 Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017
Jun 29, 2017 Pluristem to Present New Data from ARS study at Radiology Conference in U.S.
May 22, 2017 Pluristem Provides Shareholder Update on Corporate and Clinical Developments – Third Quarter 2017
May 18, 2017 Video for Shareholders- Non Human Primates Study Results for Acute Radiation Syndrome.
May 03, 2017 Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
Apr 19, 2017 Pluristem Reaches Milestone of 100 Granted Patents, Including Coverage of Leading Indications in Major Markets
Mar 30, 2017 Pluristem and Sosei CVC Advancing Towards Finalizing Joint Venture for the Commercialization of PLX-PAD in Japan
Mar 29, 2017 Pluristem Launches Co-CEO Structure and Appoints New CFO
Feb 13, 2017 Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
Jan 25, 2017 Pluristem Announces Closing of Bought Offering and Underwriter’s Exercise in Full of Over-Allotment Option
Jan 22, 2017 Pluristem Increases Previously Announced Bought Deal Offering of Common Stock and Warrants to $15,000,000
Jan 19, 2017 Pluristem Announces Bought Deal Offering
Jan 17, 2017 Pluristem Receives Clearance from Germany to Initiate its Multinational Phase III Trial in Critical Limb Ischemia Targeting Early Conditional Marketing Approval
Jan 12, 2017 Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
Jan 10, 2017 Pluristem’s Phase III Study of PLX-PAD Cells for the Treatment of Critical Limb Ischemia Cleared by U.S. FDA